Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), ProQR (PRQR) and OptimizeRx (OPRX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio (ANAB), ProQR (PRQR) and OptimizeRx (OPRX) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AnaptysBio (ANAB)
In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on AnaptysBio, with a price target of $75.00. The company’s shares closed last Tuesday at $65.58.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
Currently, the analyst consensus on AnaptysBio is a Strong Buy with an average price target of $78.27, a 16.3% upside from current levels. In a report issued on April 28, TipRanks – Google also upgraded the stock to Buy with a $74.00 price target.
See today’s best-performing stocks on TipRanks >>
ProQR (PRQR)
In a report released yesterday, Keay Nakae from Chardan Capital reiterated a Buy rating on ProQR, with a price target of $4.00. The company’s shares closed last Tuesday at $1.60, close to its 52-week low of $1.40.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of
Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $8.20.
OptimizeRx (OPRX)
In a report released yesterday, Richard Baldry from Roth MKM reiterated a Buy rating on OptimizeRx, with a price target of $18.00. The company’s shares closed last Tuesday at $6.34.
According to TipRanks.com, Baldry is a 5-star analyst with an average return of
Currently, the analyst consensus on OptimizeRx is a Strong Buy with an average price target of $15.20, implying a 148.4% upside from current levels. In a report released today, TipRanks – PerPlexity also upgraded the stock to Buy with a $7.00 price target.
Read More on ANAB:
